Takeda Pharmaceutical (TAK) holder to sell 4,319 ADSs from RSU awards

Rhea-AI Filing Summary

Takeda Pharmaceutical Company Limited has a shareholder planning to sell American Depositary Shares (ADSs). The planned sale covers up to 4,319 ADSs of Takeda, to be executed through Interactive Brokers LLC on or after July 13, 2026 on the NYSE. The securities to be sold were received as Restricted Stock Unit awards that vested on July 1, 2026, with a separate entry showing 13,988 ADSs acquired on that date as compensation.

Key Figures

ADSs planned for sale: 4,319 ADSs Market value of ADSs: $72,351.26 Planned sale date: 07/13/2026 +2 more

5 metrics

ADSs planned for sale 4,319 ADSs Proposed sale of Takeda ADSs through Interactive Brokers on the NYSE

Market value of ADSs $72,351.26 Indicated value of 4,319 Takeda ADSs planned for sale

Planned sale date 07/13/2026 Date for proposed sale of 4,319 Takeda ADSs on the NYSE

ADSs from RSU awards 13,988 ADSs Takeda ADSs acquired on 07/01/2026 from vested Restricted Stock Unit awards as compensation

RSU vesting date 07/01/2026 Date Restricted Stock Unit awards vested, resulting in 13,988 ADSs as compensation

Key Terms

American Depositary Shares, Restricted Stock Unit Awards, compensation, Interactive Brokers LLC

4 terms

American Depositary Shares financial

"American Depositary Shares (ADSs) | Interactive Brokers LLC"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

Restricted Stock Unit Awards financial

"Restricted Stock Unit Awards - Vested. | Takeda Pharmaceutical Company"

Restricted stock unit awards are company promises to deliver a specific number of shares to employees or service providers in the future once conditions—such as staying with the company for a set time or meeting performance targets—are met. They matter to investors because when the promises convert into actual shares they increase the total share count and can reduce earnings per share, while also aligning recipients’ interests with stock performance much like deferred pay that turns into ownership if goals are met.

compensation financial

"13988 | 07/01/2026 | Compensation"

Interactive Brokers LLC financial

"American Depositary Shares (ADSs) | Interactive Brokers LLC One Pickwick"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/13/2026 - 06:32 AM Accepted by SEC EDGAR 07/13/2026 - 06:23 AM Learn about SEC filing dates

FAQ

What does this Form 144-style filing indicate for Takeda (TAK)?

It indicates a Takeda shareholder plans to sell up to 4,319 ADSs on the NYSE through Interactive Brokers LLC on or after July 13, 2026, based on vested RSU compensation.

How many Takeda (TAK) ADSs are planned for sale and through whom?

The filing lists a proposed sale of 4,319 American Depositary Shares (ADSs) of Takeda Pharmaceutical Company Limited through Interactive Brokers LLC on the NYSE.

What is the approximate market value of the Takeda (TAK) ADSs to be sold?

The proposed 4,319 ADSs have an indicated market value of about $72,351.26, reflecting the value of the shares that the shareholder intends to sell.

When were the Takeda (TAK) ADSs being sold originally acquired?

The ADSs relate to Restricted Stock Unit awards that vested on July 1, 2026. A separate entry shows 13,988 ADSs acquired on that date as compensation.

On what date is the Takeda (TAK) ADS sale expected to occur?

The sale of up to 4,319 ADSs is listed with a planned sale date of July 13, 2026 on the NYSE, subject to execution through the broker.

What type of security is involved in this Takeda (TAK) planned sale?

The security is American Depositary Shares (ADSs) of Takeda Pharmaceutical Company Limited, including shares received from vested RSU compensation on July 1, 2026.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
American Depositary Shares (ADSs)	Interactive Brokers LLC One Pickwick Plaza Greenwich CT 06830	4319	72351.26	143310556	07/13/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
ADSs	07/01/2026	Restricted Stock Unit Awards - Vested.	Takeda Pharmaceutical Company Limited			13988	07/01/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)